Consolidated Statements of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 4,000	$ 596,724		$ (3,842,186)	$ (3,241,462)
Balance (in Shares) at Dec. 31, 2018	4,000,000
Issuance of common stock in connection with IPO, including underwriter’s over- allotment, net of offering costs and underwriter’s discount	$ 4,879	21,748,969			21,753,848
Issuance of common stock in connection with IPO, including underwriter’s over- allotment, net of offering costs and underwriter’s discount (in Shares)	4,879,300
Stock-based compensation		590,041			590,041
Dividends on preferred stock		(875,359)			(875,359)
Conversion of Series A Preferred Stock (including accrued dividends) to common stock	$ 9,572	21,278,335			21,287,907
Conversion of Series A Preferred Stock (including accrued dividends) to common stock (in Shares)	9,571,692
Net loss				(11,870,228)	(11,870,228)
Balance at Dec. 31, 2019	$ 18,451	43,338,710		(15,712,414)	27,644,747
Balance (in Shares) at Dec. 31, 2019	18,450,992
Sale of common stock, net of offering costs	$ 3,048	24,277,235			24,280,283
Sale of common stock, net of offering costs (in Shares)	3,048,654
Issuance of common stock for accrued research and development expense	$ 221	1,131,792			1,132,013
Issuance of common stock for accrued research and development expense (in Shares)	220,666
Issuance of common stock for stock option exercises	$ 285	714,097			714,382
Issuance of common stock for stock option exercises (in Shares)	285,003
Issuance of common stock in connection with cashless warrant exercises	$ 530	(530)
Issuance of common stock in connection with cashless warrant exercises (in Shares)	529,559
Stock-based compensation		2,187,149			2,187,149
Foreign currency translation adjustment			(51,538)		(51,538)
Net loss				(18,567,234)	(18,567,234)
Balance at Dec. 31, 2020	$ 22,535	$ 71,648,453	$ (51,538)	$ (34,279,648)	$ 37,339,802
Balance (in Shares) at Dec. 31, 2020	22,534,874